stockrow
Saturday 7 November 2026
Export OGEN’s income statement to Excel — free account
Oragenics, Inc.
OGEN Healthcare Biotechnology
Oragenics, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $37,700.00, down 71.3% from fiscal 2022.
- EPS
- +81.6%
- Free cash flow
- −66.4%
Quarter to June 2026, against a year earlier
0.35
0.00
0.00%
Follow OGEN
Alert me
Oragenics, Inc. (OGEN) P/E ratio
Oragenics, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 0.0× (November 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Sep 2023 | 0.0× | — |
| Jun 2023 | 0.0× | — |
| Mar 2023 | 0.0× | — |
| Sep 2022 | 0.0× | — |
| 4 more quarters | Free account |
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| CARM Carisma Therapeutics Inc. compare | n/m |
| GNPX GENPREX compare | n/m |
| PPCB Propanc Biopharma Inc compare | n/m |
| XRTX XORTX Therapeutics Inc. compare | n/m |
| GOVX GeoVax Labs Inc. compare | n/m |
| KAPA Kairos Pharma, Ltd. compare | n/m |
| VRAX Virax Biolabs Group Limited compare | n/m |
| ITRMF Iterum Therapeutics PLC compare | n/m |
| OGEN Oragenics, Inc. | n/m |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)